Hearing Handicap clinical trials

Explore recruiting hearing handicap clinical trials.

Recruiting hearing handicap studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hearing Handicap trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase II, Multi-Center, Randomized, Blinded Study Evaluating the Efficacy, Safety and Tolerability of a Single Intratympanic Dose of AC102 Compared to Oral Steroids for the Treatment of Idiopathic Sudden Sensorineural Hearing Loss

Poland, Czechia, Germany, Austria, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

NRG-HN009: RANDOMIZED PHASE II/III TRIAL OF RADIATION WITH CISPLATIN AT 100 MG/M2 EVERY THREE WEEKS VERSUS RADIATION WITH WEEKLY CISPLATIN AT 40 MG/M2 FOR PATIENTS WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN).

Ireland

Phase II and Phase III (Integrated) EU CTIS Study details

Hearing Handicap trials by city

Hearing Handicap in Toronto Hearing Handicap in Vancouver Hearing Handicap in Montreal Hearing Handicap in Calgary Hearing Handicap in Edmonton Hearing Handicap in Ottawa Hearing Handicap in Winnipeg Hearing Handicap in Quebec City Hearing Handicap in Hamilton Hearing Handicap in Kitchener Hearing Handicap in London Hearing Handicap in Halifax Hearing Handicap in New York Hearing Handicap in Los Angeles Hearing Handicap in Chicago Hearing Handicap in Houston

Hearing Handicap clinical trials

Recruiting hearing handicap studies right now

A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound

Evaluation of Deep Brain Stimulation (DBS) of the Right Operculum 3 (OP3) in Permanent Non-pulsatile Disabling Tinnitus (TINNOP3-DBS)

Mediators and Moderators of Auditory Training

Also recruiting in Europe

Phase II, Multi-Center, Randomized, Blinded Study Evaluating the Efficacy, Safety and Tolerability of a Single Intratympanic Dose of AC102 Compared to Oral Steroids for the Treatment of Idiopathic Sudden Sensorineural Hearing Loss

NRG-HN009: RANDOMIZED PHASE II/III TRIAL OF RADIATION WITH CISPLATIN AT 100 MG/M2 EVERY THREE WEEKS VERSUS RADIATION WITH WEEKLY CISPLATIN AT 40 MG/M2 FOR PATIENTS WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN).

Hearing Handicap trials by city

Other conditions